[4] [5] The standard of care remains disease-modifying antirheumatic drugs (DMARDs), including conventional synthetic DMARDs like methotrexate as first-line therapy, with escalation to biological DMARDs or targeted synthetic DMARDs if disease activity remains inadequately controlled, following a treat-to-target approach
Notably, GLP-1R deletion in primary mouse astrocytes results in subtle mitochondrial dysfunction accompanied by a compensatory enhancement of glucose transporter-1-mediated aerobic glycolysis [22]
As an expert in bioidentical hormone replacement therapy, Dr
Gil-Lozano M, Romani-Prez M, Outeirio-Iglesias V, Vigo E, Gonzlez-Matas LC, Brubaker PL, et al
For comprehensive coverage, explore peptides for anti-aging applications and mechanisms